SlideShare una empresa de Scribd logo
1 de 6
Find Industry reports, Company profiles
ReportLinker                                                                           and Market Statistics
                                               >> Get this Report Now by email!



Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012
Published on December 2012

                                                                                                               Report Summary

Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012


Summary


Global Market Direct's pharmaceuticals report, "Amorfix Life Sciences Ltd. - Product Pipeline Review - 2012" provides data on the
Amorfix Life Sciences Ltd.'s research and development focus. The report includes information on current developmental pipeline,
complete with latest updates, and features on discontinued and dormant projects.


This report is built using data and information sourced from Global Markets Direct's proprietary databases, Amorfix Life Sciences
Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Amorfix Life Sciences Ltd. and
industry-specific third party sources, put together by Global Markets Direct's team.


Scope


- Amorfix Life Sciences Ltd. - Brief Amorfix Life Sciences Ltd. overview including business description, key information and facts, and
its locations and subsidiaries.
- Review of current pipeline of Amorfix Life Sciences Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Amorfix Life Sciences Ltd. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Amorfix Life Sciences Ltd.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Amorfix Life Sciences Ltd.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Amorfix Life Sciences Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Amorfix Life Sciences Ltd.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Amorfix Life Sciences Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Amorfix Life Sciences Ltd. and identify potential opportunities in those areas.




Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare)                                                    Page 1/6
Find Industry reports, Company profiles
ReportLinker                                                                           and Market Statistics
                                               >> Get this Report Now by email!



                                                                                                      Table of Content

Table of Contents


Table of Contents 2
List of Tables 4
List of Figures 5
Amorfix Life Sciences Ltd. Snapshot 6
Amorfix Life Sciences Ltd. Overview 6
Key Information 6
Key Facts 6
Amorfix Life Sciences Ltd. ' Research and Development Overview 7
Key Therapeutic Areas 7
Amorfix Life Sciences Ltd. ' Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products ' Monotherapy 10
Amorfix Life Sciences Ltd. ' Pipeline Products Glance 11
Amorfix Life Sciences Ltd. ' Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Amorfix Life Sciences Ltd. ' Drug Profiles 13
ALS Therapeutic Vaccine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Anti-CD38 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Anti-Fas 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Anti-PrP Antibody 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Antibodies Against Cancer 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Amorfix Life Sciences Ltd. ' Pipeline Analysis 19
Amorfix Life Sciences Ltd. ' Pipeline Products by Therapeutic Class 19
Amorfix Life Sciences Ltd. ' Pipeline Products By Mechanism of Action 20
Amorfix Life Sciences Ltd. ' Recent Pipeline Updates 21
Amorfix Life Sciences Ltd. ' Company Statement 22



Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare)                                     Page 2/6
Find Industry reports, Company profiles
ReportLinker                                                                           and Market Statistics
                                               >> Get this Report Now by email!

Amorfix Life Sciences Ltd. ' Locations And Subsidiaries 24
Head Office 24
Financial Deals Landscape 25
Amorfix Life Sciences Ltd., Deals Summary 25
Amorfix Life Sciences Ltd., Pharmaceuticals & Healthcare, Deal Details 27
Asset Transactions 27
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 27
Partnerships 28
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 28
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 30
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 31
Amorfix Life Sciences Enters Into Co-Development Agreement With QED Bioscience 32
Amorfix Life Sciences Enters Into An Agreement With Aragen Bioscience 33
Amorfix Enters Into Co-Development Agreement With Epitomics 34
Amorfix Life Sciences Enters Into An Agreement With BioMosaics 35
Amorfix Enters Into Co-Development Agreement With The University Of British Columbia 36
Amorfix Enters Into Co-Development Agreement With University Of British Columbia 37
Amorfix Signs An Agreement With Ontario Genomics 38
Licensing Agreements 39
Pan-Provincial Vaccine Enters Into Licensing Agreement With Amorfix Life Sciences 39
Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 40
Amorfix Life Sciences Enters Into Licensing Agreement With PREVENT 41
Amorfix Life Sciences Enters Into Licensing Agreement With University of British Columbia 42
Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 43
Amorfix Life Sciences Enters Into Licensing Agreement With University Health Network 44
Amorfix Life Sciences Enters Into Licensing Agreement With Dr. Neil Cashman 45
Equity Offering 46
Amorfix Life Sciences Completes Private Placement Of Units For $1 Million 46
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For $0.08 Million 47
Amorfix Life Sciences Completes Private Placement Of $0.51 Million 49
Amorfix Life Sciences Completes Private Placement Of $2.71 Million 51
Amorfix Completes Bought Deal Private Placement Of $8.63 Million 53
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 55
Amorfix Completes Private Placement Of $3.04 Million 56
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60




List of Tables




Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare)                                     Page 3/6
Find Industry reports, Company profiles
ReportLinker                                                                           and Market Statistics
                                               >> Get this Report Now by email!

Amorfix Life Sciences Ltd., Key Information 6
Amorfix Life Sciences Ltd., Key Facts 6
Amorfix Life Sciences Ltd. ' Pipeline by Indication, 2012 8
Amorfix Life Sciences Ltd. ' Pipeline by Stage of Development, 2012 9
Amorfix Life Sciences Ltd. ' Monotherapy Products in Pipeline, 2012 10
Amorfix Life Sciences Ltd. ' Pre-Clinical, 2012 11
Amorfix Life Sciences Ltd. ' Discovery, 2012 12
Amorfix Life Sciences Ltd. ' Pipeline By Therapeutic Class, 2012 19
Amorfix Life Sciences Ltd. ' Pipeline Products By Mechanism of Action, 2012 20
Amorfix Life Sciences Ltd. ' Recent Pipeline Updates, 2012 21
Amorfix Life Sciences Ltd., Deals Summary 25
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 27
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 28
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 30
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 31
Amorfix Life Sciences Enters Into Co-Development Agreement With QED Bioscience 32
Amorfix Life Sciences Enters Into An Agreement With Aragen Bioscience 33
Amorfix Enters Into Co-Development Agreement With Epitomics 34
Amorfix Life Sciences Enters Into An Agreement With BioMosaics 35
Amorfix Enters Into Co-Development Agreement With The University Of British Columbia 36
Amorfix Enters Into Co-Development Agreement With University Of British Columbia 37
Amorfix Signs An Agreement With Ontario Genomics 38
Pan-Provincial Vaccine Enters Into Licensing Agreement With Amorfix Life Sciences 39
Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 40
Amorfix Life Sciences Enters Into Licensing Agreement With PREVENT 41
Amorfix Life Sciences Enters Into Licensing Agreement With University of British Columbia 42
Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 43
Amorfix Life Sciences Enters Into Licensing Agreement With University Health Network 44
Amorfix Life Sciences Enters Into Licensing Agreement With Dr. Neil Cashman 45
Amorfix Life Sciences Completes Private Placement Of Units For $1 Million 46
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For $0.08 Million 47
Amorfix Life Sciences Completes Private Placement Of $0.51 Million 49
Amorfix Life Sciences Completes Private Placement Of $2.71 Million 51
Amorfix Completes Bought Deal Private Placement Of $8.63 Million 53
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 55
Amorfix Completes Private Placement Of $3.04 Million 56
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 58




List of Figures


Amorfix Life Sciences Ltd. ' Pipeline by Indication, 2012 8
Amorfix Life Sciences Ltd. ' Pipeline by Stage of Development, 2012 9
Amorfix Life Sciences Ltd. ' Monotherapy Products in Pipeline, 2012 10
Amorfix Life Sciences Ltd. ' Pipeline By Therapeutic Class, 2012 19
Amorfix Life Sciences Ltd. - Pipeline Products By Mechanism of Action, 2012 20




Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare)                                     Page 4/6
Find Industry reports, Company profiles
ReportLinker                                                                                  and Market Statistics
                                               >> Get this Report Now by email!
              Fax Order Form
              To place an order via fax simply print this form, fill in the information below and fax the completed form to:
                            Europe, Middle East and Africa : + 33 4 37 37 15 56
                            Asia, Oceania and America : + 1 (805) 617 17 93
              If you have any questions please visit http://www.reportlinker.com/notify/contact


              Order Information
              Please verify that the product information is correct and select the format(s) you require.

                     Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012




              Product Formats
              Please select the product formats and the quantity you require.

                                       1 User License--USD 1 500.00                  Quantity: _____



                                       Site License--USD 3 000.00                    Quantity: _____



                                       Corporate License--USD 4 500.00               Quantity: _____




              Contact Information
              Please enter all the information below in BLOCK CAPITALS


              Title:                     Mr                        Mrs          Dr             Miss         Ms                 Prof

              First Name:                     _____________________________ Last Name: __________________________________

              Email Address:                __________________________________________________________________________

              Job Title:                    __________________________________________________________________________

              Organization:                 __________________________________________________________________________

              Address:                      __________________________________________________________________________

              City:                         __________________________________________________________________________

              Postal / Zip Code:              __________________________________________________________________________

              Country:                      __________________________________________________________________________

              Phone Number:                 __________________________________________________________________________

              Fax Number:                   __________________________________________________________________________




Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare)                                                         Page 5/6
Find Industry reports, Company profiles
ReportLinker                                                                                          and Market Statistics
                                               >> Get this Report Now by email!
              Payment Information
              Please indicate the payment method, you would like to use by selecting the appropriate box.




                      Payment by credit card                         Card Number: ______________________________________________


                                                                     Expiry Date     __________ / _________


                                                                     CVV Number _____________________


                                                                     Card Type (ex: Visa, Amex…) _________________________________




                      Payment by wire transfer                       Crédit Mutuel
                                                                     RIB : 10278 07314 00020257701 89
                                                                     BIC : CMCIFR2A
                                                                     IBAN : FR76 1027 8073 1400 0202 5770 189




                       Payment by check                              UBIQUICK SAS
                                                                     16 rue Grenette – 69002 LYON, FRANCE




                                    Customer signature:

                                     




              Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
              http://www.reportlinker.com/index/terms




                                                                        Please fax this form to:

                                                         Europe, Middle East and Africa : + 33 4 37 37 15 56

                                                           Asia, Oceania and America : + 1 (805) 617 17 93




Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare)                                                        Page 6/6

Más contenido relacionado

Más de ReportLinker.com

Global Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryGlobal Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryReportLinker.com
 
Global Wireless Gaming Industry
Global Wireless Gaming IndustryGlobal Wireless Gaming Industry
Global Wireless Gaming IndustryReportLinker.com
 
Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
 
The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
 
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
 
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
 
Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
 
China iron ore mining industry, 2013
China iron ore mining industry, 2013China iron ore mining industry, 2013
China iron ore mining industry, 2013ReportLinker.com
 
Global Renewable Energy Report
Global Renewable Energy ReportGlobal Renewable Energy Report
Global Renewable Energy ReportReportLinker.com
 
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013ReportLinker.com
 

Más de ReportLinker.com (20)

 
Thisisatest
ThisisatestThisisatest
Thisisatest
 
Global Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryGlobal Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes Industry
 
Global Wireless Gaming Industry
Global Wireless Gaming IndustryGlobal Wireless Gaming Industry
Global Wireless Gaming Industry
 
Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013
 
Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013
 
The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...
 
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
 
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
 
Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013
 
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
 
China iron ore mining industry, 2013
China iron ore mining industry, 2013China iron ore mining industry, 2013
China iron ore mining industry, 2013
 
World Biomass Report
World Biomass ReportWorld Biomass Report
World Biomass Report
 
World Biofuels Report
World Biofuels ReportWorld Biofuels Report
World Biofuels Report
 
Global Renewable Energy Report
Global Renewable Energy ReportGlobal Renewable Energy Report
Global Renewable Energy Report
 
Solar PV Report
Solar PV ReportSolar PV Report
Solar PV Report
 
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013Inguinal Hernia Global Clinical Trials Review, H1, 2013
Inguinal Hernia Global Clinical Trials Review, H1, 2013
 
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013Cancer Cachexia Global Clinical Trials Review, H1, 2013
Cancer Cachexia Global Clinical Trials Review, H1, 2013
 
Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013Pompe Disease Global Clinical Trials Review, H1, 2013
Pompe Disease Global Clinical Trials Review, H1, 2013
 
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
 

Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012

  • 1. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 Published on December 2012 Report Summary Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 Summary Global Market Direct's pharmaceuticals report, "Amorfix Life Sciences Ltd. - Product Pipeline Review - 2012" provides data on the Amorfix Life Sciences Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Amorfix Life Sciences Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Amorfix Life Sciences Ltd. and industry-specific third party sources, put together by Global Markets Direct's team. Scope - Amorfix Life Sciences Ltd. - Brief Amorfix Life Sciences Ltd. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Amorfix Life Sciences Ltd. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Amorfix Life Sciences Ltd. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Amorfix Life Sciences Ltd.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Amorfix Life Sciences Ltd.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Amorfix Life Sciences Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Amorfix Life Sciences Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Amorfix Life Sciences Ltd.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Amorfix Life Sciences Ltd. and identify potential opportunities in those areas. Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6
  • 2. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Table of Content Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Amorfix Life Sciences Ltd. Snapshot 6 Amorfix Life Sciences Ltd. Overview 6 Key Information 6 Key Facts 6 Amorfix Life Sciences Ltd. ' Research and Development Overview 7 Key Therapeutic Areas 7 Amorfix Life Sciences Ltd. ' Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products ' Monotherapy 10 Amorfix Life Sciences Ltd. ' Pipeline Products Glance 11 Amorfix Life Sciences Ltd. ' Early Stage Pipeline Products 11 Pre-Clinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Amorfix Life Sciences Ltd. ' Drug Profiles 13 ALS Therapeutic Vaccine 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Anti-CD38 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Anti-Fas 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Anti-PrP Antibody 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Antibodies Against Cancer 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Amorfix Life Sciences Ltd. ' Pipeline Analysis 19 Amorfix Life Sciences Ltd. ' Pipeline Products by Therapeutic Class 19 Amorfix Life Sciences Ltd. ' Pipeline Products By Mechanism of Action 20 Amorfix Life Sciences Ltd. ' Recent Pipeline Updates 21 Amorfix Life Sciences Ltd. ' Company Statement 22 Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/6
  • 3. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Amorfix Life Sciences Ltd. ' Locations And Subsidiaries 24 Head Office 24 Financial Deals Landscape 25 Amorfix Life Sciences Ltd., Deals Summary 25 Amorfix Life Sciences Ltd., Pharmaceuticals & Healthcare, Deal Details 27 Asset Transactions 27 Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 27 Partnerships 28 Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 28 Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 30 Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 31 Amorfix Life Sciences Enters Into Co-Development Agreement With QED Bioscience 32 Amorfix Life Sciences Enters Into An Agreement With Aragen Bioscience 33 Amorfix Enters Into Co-Development Agreement With Epitomics 34 Amorfix Life Sciences Enters Into An Agreement With BioMosaics 35 Amorfix Enters Into Co-Development Agreement With The University Of British Columbia 36 Amorfix Enters Into Co-Development Agreement With University Of British Columbia 37 Amorfix Signs An Agreement With Ontario Genomics 38 Licensing Agreements 39 Pan-Provincial Vaccine Enters Into Licensing Agreement With Amorfix Life Sciences 39 Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 40 Amorfix Life Sciences Enters Into Licensing Agreement With PREVENT 41 Amorfix Life Sciences Enters Into Licensing Agreement With University of British Columbia 42 Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 43 Amorfix Life Sciences Enters Into Licensing Agreement With University Health Network 44 Amorfix Life Sciences Enters Into Licensing Agreement With Dr. Neil Cashman 45 Equity Offering 46 Amorfix Life Sciences Completes Private Placement Of Units For $1 Million 46 Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For $0.08 Million 47 Amorfix Life Sciences Completes Private Placement Of $0.51 Million 49 Amorfix Life Sciences Completes Private Placement Of $2.71 Million 51 Amorfix Completes Bought Deal Private Placement Of $8.63 Million 53 Amorfix Life Sciences Completes Private Placement Of $0.05 Million 55 Amorfix Completes Private Placement Of $3.04 Million 56 Amorfix Life Sciences Completes Private Placement Of $0.05 Million 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60 List of Tables Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/6
  • 4. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Amorfix Life Sciences Ltd., Key Information 6 Amorfix Life Sciences Ltd., Key Facts 6 Amorfix Life Sciences Ltd. ' Pipeline by Indication, 2012 8 Amorfix Life Sciences Ltd. ' Pipeline by Stage of Development, 2012 9 Amorfix Life Sciences Ltd. ' Monotherapy Products in Pipeline, 2012 10 Amorfix Life Sciences Ltd. ' Pre-Clinical, 2012 11 Amorfix Life Sciences Ltd. ' Discovery, 2012 12 Amorfix Life Sciences Ltd. ' Pipeline By Therapeutic Class, 2012 19 Amorfix Life Sciences Ltd. ' Pipeline Products By Mechanism of Action, 2012 20 Amorfix Life Sciences Ltd. ' Recent Pipeline Updates, 2012 21 Amorfix Life Sciences Ltd., Deals Summary 25 Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 27 Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 28 Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 30 Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 31 Amorfix Life Sciences Enters Into Co-Development Agreement With QED Bioscience 32 Amorfix Life Sciences Enters Into An Agreement With Aragen Bioscience 33 Amorfix Enters Into Co-Development Agreement With Epitomics 34 Amorfix Life Sciences Enters Into An Agreement With BioMosaics 35 Amorfix Enters Into Co-Development Agreement With The University Of British Columbia 36 Amorfix Enters Into Co-Development Agreement With University Of British Columbia 37 Amorfix Signs An Agreement With Ontario Genomics 38 Pan-Provincial Vaccine Enters Into Licensing Agreement With Amorfix Life Sciences 39 Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 40 Amorfix Life Sciences Enters Into Licensing Agreement With PREVENT 41 Amorfix Life Sciences Enters Into Licensing Agreement With University of British Columbia 42 Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 43 Amorfix Life Sciences Enters Into Licensing Agreement With University Health Network 44 Amorfix Life Sciences Enters Into Licensing Agreement With Dr. Neil Cashman 45 Amorfix Life Sciences Completes Private Placement Of Units For $1 Million 46 Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For $0.08 Million 47 Amorfix Life Sciences Completes Private Placement Of $0.51 Million 49 Amorfix Life Sciences Completes Private Placement Of $2.71 Million 51 Amorfix Completes Bought Deal Private Placement Of $8.63 Million 53 Amorfix Life Sciences Completes Private Placement Of $0.05 Million 55 Amorfix Completes Private Placement Of $3.04 Million 56 Amorfix Life Sciences Completes Private Placement Of $0.05 Million 58 List of Figures Amorfix Life Sciences Ltd. ' Pipeline by Indication, 2012 8 Amorfix Life Sciences Ltd. ' Pipeline by Stage of Development, 2012 9 Amorfix Life Sciences Ltd. ' Monotherapy Products in Pipeline, 2012 10 Amorfix Life Sciences Ltd. ' Pipeline By Therapeutic Class, 2012 19 Amorfix Life Sciences Ltd. - Pipeline Products By Mechanism of Action, 2012 20 Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/6
  • 5. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 1 500.00 Quantity: _____ Site License--USD 3 000.00 Quantity: _____ Corporate License--USD 4 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________ Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/6
  • 6. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/6